Nanjing Leads Biolabs Co., Ltd (“Leads Biolabs” or “company”), a Nanjing-based biotech specialized in the development of tumor immunotherapy, announced successful completion of a new round of financing, raising nearly 100 million RMB. This financing was jointly funded by existing investors including Shanghai CCB Capital, Ennovation Venture, and New Vision Capital, as well as new investors including Huafang Capital and Huaige Capital. The proceeds will be primarily used to support clinical development of the company’s lead drug candidates as well as to accelerate other preclinical projects and talent recruiting.
Leads Biolabs is committed to developing novel proprietary antibody drugs focusing on tumor immunotherapy. In 2015 and 2017, it completed two rounds of financing. Leads Biolabs has established a proprietary pipeline consisting more than ten new-mechanism tumor immunotherapy antibodies based on its innovative discovery platform.
Regarding the close of the financing, the founder, chairman and CEO of the company, Dr. Kang Xiaoqiang remarked, "We are thankful to our existing and new shareholders for their trust, support and recognition of our platform and pipeline.”
Huaige Capital is a private equity fund focusing on healthcare industry, driven by strategies combining “active investing”and “in-depth investment banking services”. The management team of Huaige Capital is with extensive industry and equity investment experience. Its portfolio includes KDL Medical (1501.HK, interventional medical devices), Cofoe Medical (domestic medical devices), Ouwen Medical (distribution platform), Bestudy (clinical CRO), Biosense (chemical drug), Leads Biolabs (biologic drug), Leto Laboratories (protein engineering), Resproly(inhaled drug) and Zhongyi Anke (human vaccine) and so on.
